反応式
[CH3:1][N:2]1[C:6]([CH3:7])=[C:5]([CH2:8][N:9]2[CH2:14][CH2:13][N:12]([C:15]3[C:20]([C:21]4[CH:28]=[CH:27][C:24]([CH2:25][NH2:26])=[CH:23][CH:22]=4)=[N:19][CH:18]=[CH:17][N:16]=3)[CH2:11][CH2:10]2)[CH:4]=[N:3]1.[CH3:29][O:30][CH2:31][C:32](Cl)=[O:33].N1CCOCC1>C(Cl)Cl>[CH3:1][N:2]1[C:6]([CH3:7])=[C:5]([CH2:8][N:9]2[CH2:10][CH2:11][N:12]([C:15]3[C:20]([C:21]4[CH:22]=[CH:23][C:24]([CH2:25][NH:26][C:32](=[O:33])[CH2:31][O:30][CH3:29])=[CH:27][CH:28]=4)=[N:19][CH:18]=[CH:17][N:16]=3)[CH2:13][CH2:14]2)[CH:4]=[N:3]1参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
Dissolve 4-[4-(1,5-dimethyl-1H-pyrazol-4-ylmethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyrazinyl-3′-yl]-benzylamine (0.2 g, 0.53 mmol) in methylene chloride (5 mL). Add methoxy-acetyl chloride (1 eq., 0.058 g, 0.53 mmol). Add polymer bounded morpholine (1.1 eq., 0.234 g, 0.58 mmol). Stir at room temperature for 3 hr. Purify by SCX followed by reverse phase chromatography to give free base N-{4-[4-(1,5-dimethyl-1H-pyrazol-4-ylmethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyrazinyl-3′-yl]-benzyl}-2-methoxy-acetamide, (0.051 g, 21%). MS (ES): m/z=450.3 [M+H].
後処理
- customPurify by SCX
出典と根拠
- ORDレコード
- ord-fb2f87db8081447b9e19470820149883
- 出典データセット
- uspto-grants-2012_06
- 特許番号
- US08202873B2
関連ノート
読み込み中…